Results 131 to 140 of about 89,572 (287)

Docetaxel in the treatment of squamous cell carcinoma of the head and neck

, 2008
Alexander Rapidis1, Nicholas Sarlis2, Jean-Louis Lefebvre3, Merrill Kies41Department of Maxillofacial Surgery, Greek Anticancer Institute, Saint Savvas Hospital, Athens, Greece; 2Department of Medical Affairs, Oncology – US Sanofi-Aventis ...
Alexander Rapidis, Nicholas Sarlis, Jean-Louis Lefebvre, Merrill Kies   +3 more
core  

Docetaxel.

, 1995
PURPOSE We reviewed the preclinical and clinical profiles of the antineoplastic taxoid docetaxel (Taxotere, Rhône-Poulenc Rorer, Collegeville, PA). DESIGN From the literature and manufacturer's data, we detail docetaxel's activity, tolerability, and ...
J E Cortes, R Pazdur
core   +1 more source

Outcomes for Patients With Micro‐Invasive or Small HER2+ Breast Cancer in Northern Sydney Local Health District

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This retrospective study of patients with small, node‐negative HER2+ breast cancer found favorable 5‐year invasive disease‐free survival rates—93% for pT1mic/a disease and 100% for pT1b disease. Trastuzumab was administered to 66% of patients and was associated with larger tumor size and higher histologic grade.
Yuanyuan Xue, Katrina Moore, Tricia Saurine, David Chan, Lina Pugliano, Connie Diakos   +5 more
wiley   +1 more source

Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott, Eugene Moylan, Maree Colosimo, Giles Stratton, Thomas Chiu, Mahsa H. Kouhkamari, Maureen Hitschfeld, Jessica Michie, Richard De Boer   +8 more
wiley   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

Clinical pharmacodynamic factors in docetaxel toxicity

, 2007
International audienceNeutropenia is the main dose-limiting toxicity occurring in docetaxel treatment. The objective of this study was to identify pharmacodynamic (PD) factors responsible for the neutropaenia caused by docetaxel.
Raoul, V, Goldwasser, F, V Raoul, F Puisset, Roché, H, F Goldwasser, J-M Treluyer, E Chatelut, Alexandre, J, J Alexandre, Puisset, F, H Roché, Chatelut, E, Treluyer, J-M   +13 more
core   +1 more source

Targeting hexokinase 2 to induce breast cancer cell senescence

British Journal of Pharmacology, EarlyView.
Background and Purpose Hexokinase 2 (HK2) is a key enzyme linked to high tumour cell proliferation. Its inhibitors such as 3‐bromopyruvic acid (3‐BP) induce cancer cell death, highlighting HK2 modulation as potential anti‐cancer treatment. However, standard chemotherapies often cause the emergence of senescent cancer cells, which goes along with cell ...
Helmut Bischof, Katarina Cisarova, Sandra Burgstaller, Mia Schwerer, Markus Absenger‐Novak, Philipp J. Jost, Roland Malli, Wolfgang F. Graier, Robert Lukowski   +8 more
wiley   +1 more source

Docetaxel induced activation of GSDME pathway and pyroptosis enhance immune lethality in prostate cancer cells

Journal of Experimental & Clinical Cancer Research
Background Immunotherapy has emerged as a promising approach in prostate cancer treatment, albeit with less efficacy compared to lung and esophageal cancers.
Ruoyang Liu, Long Zhang, Guoqing Xie, Xiang Li, Yu Liu, Ningyang Li, Aravind Raveendran, Yuankang Feng, Fubo Lu, Xiyue Deng, Junyi Li, Jinjian Yang, Zhenlin Huang, Zhankui Jia   +13 more
doaj   +1 more source

Modulation of docetaxel treatment [PDF]

, 1997
The taxanes are a new class of drugs that exert antitumor activity through a unique mechanism. As early as in the late 1960s paclitaxel, extracted from the bark of the Pacific Yew Taxus Brevifolia, was the first compound with a taxene ring that exhibited
Pronk, L.C. (Linda), Pronk, LC
core  

Ischaemic stroke and 5‐fluorouracil or capecitabine: A systematic review and meta‐analysis of harms and a retrospective study of the WHO pharmacovigilance database

British Journal of Pharmacology, EarlyView.
Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen, Ines Bentahrour, Camille Guerin, Charles Dolladille, Angélique Da Silva, François Cherifi, Elise‐Marie Minoc, Pierre‐Marie Morice, Nicolas Jacquin, Christophe Le Tourneau, Joachim Alexandre, Ahmad Nehme, Etienne Bastien   +12 more
wiley   +1 more source